{[ promptMessage ]}

Bookmark it

{[ promptMessage ]}

anthro 101 - Race-based Medicine (93-03)

anthro 101 - Race-based Medicine (93-03) - Diokno Laya...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
Diokno, Laya Elena A. February 20, 2009 Navarro, Lorina Ann M. Position Paper The Truth Behind the Race-Based Medicine In the United States, African-Americans are shown to be 50% more likely to develop heart failure as compared to other ethnic groups, and they are more likely to develop this early in life with symptoms more severe, leading to hospitalization and deaths from this condition. Heart failure develops in African Americans more because of higher rate of high blood pressure and diabetes, as well as, African Americans’ lower access to and use of health care services, greater exposure to environmental pollutants, and greater tendencies to be overweight and to get less exercise (“BiDil”, 2004). In 2004, the drug, BiDil which is composed of isosorbide dinitrate and hydralazine hydrochloride was approved by the U.S. FDA (Food and Drug Administration). BiDil is a designed to treat heart failure in self identified African Americans. It is the first Race-based medicine. Since the approval of the drug, there have been many questions regarding the ethics and the biological aspect of what the drug entails, which is a medicine designed for a certain race, as well as questions on the development of the drug, its trial and approval. Its approval consequently fueled much discussion over the use of the term “race” in treating medical conditions and the implications of having a drug that is restricted to one racial category. One of the most noted and controversial articles the this debate is evolutionary biologist Armand Leroi's article, “A Family Tree in Every Gene,” in which he argues that race is a “vital shorthand that enables people to speak sensibly about genetic rather than cultural or political differences” and that its uses will reap benefits such as improved medical care and treatment, as different races are prone to different illnesses from their specific characteristics (Leroi 2005). Inevitably, his article spawned backlash in the scientific community, and he was criticized for his simplistic framing of race and also his disregard for the social causes for disease. The issue of BiDil and Dr. Leroi's article are both constituents of the greater issue that is the use of race in medicine. While the consensus among anthropologists is that race is a social construct based on distinct physical variation among people who belong in a certain population, and, more importantly, a non-biological entity and a byproduct of historical and contemporary social, economic, educational, and political circumstances (AAA, 1998), some scientists, however, the upsurge of genetic testing in the nineties and up to the present has given some scientists the opinion that there is significant biological variation between different racial and ethnic groups in disease 1
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
susceptibility and drug response and that knowledge of these differences would be useful for medical diagnosis and treatment (Fujimura, Duster & Rajagopalan, 2008).
Background image of page 2
Image of page 3
This is the end of the preview. Sign up to access the rest of the document.

{[ snackBarMessage ]}